Indian hospitals witness a surge in infant respiratory infections during monsoon and winter, often due to Respiratory Syncytial Virus (RSV). Highly co ...

Frailty was a significant predictor of severe outcomes and hospitalization characteristics in older adults hospitalized with RSV infection.

Medical experts in India are calling for urgent attention to Respiratory Syncytial Virus (RSV), a highly contagious but under ...

Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

Respiratory syncytial virus (RSV) infections were associated with significantly increased risk for complications beyond ...

“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

London: GSK plc has announced that the US Food and Drug Administration (FDA) has accepted for review an application to extend ...

GSK announces US FDA accepts application to review expanded use of RSV vaccine, Arexvy for adults 18-49 at increased risk: London, UK Wednesday, July 16, 2025, 14:00 Hrs [IST] GSK ...

The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and diagnostic measures in healthcare.